BioLineRx Ltd. (BLRX)
Sector: Pharmaceutical Preparations
Industry: Biotechnology
BioLineRx Ltd.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 17, 2026 | 1.19 | 1.29 | 1.11 | 1.12 | 33,181 |
| Nov 16, 2026 | 1.25 | 1.37 | 1.14 | 1.15 | 16,582 |
| Nov 13, 2026 | 1.37 | 1.54 | 1.30 | 1.30 | 14,107 |
| Nov 12, 2026 | 1.56 | 1.60 | 1.35 | 1.35 | 11,472 |
| Nov 11, 2026 | 1.55 | 1.63 | 1.48 | 1.49 | 6,363 |
| Nov 10, 2026 | 1.70 | 1.75 | 1.45 | 1.52 | 7,684 |
| Nov 9, 2026 | 1.64 | 1.71 | 1.58 | 1.58 | 28,268 |
| Nov 6, 2026 | 1.72 | 1.75 | 1.71 | 1.71 | 8,483 |
| Nov 5, 2026 | 1.92 | 1.92 | 1.70 | 1.77 | 15,158 |
| Nov 4, 2026 | 1.81 | 1.92 | 1.81 | 1.86 | 8,883 |
| Nov 3, 2026 | 1.94 | 1.99 | 1.90 | 1.91 | 13,373 |
| Nov 2, 2026 | 1.94 | 1.96 | 1.94 | 1.96 | 4,705 |
| Oct 30, 2026 | 1.95 | 1.99 | 1.94 | 1.99 | 8,792 |
| Oct 29, 2026 | 2.01 | 2.02 | 1.94 | 2.02 | 4,149 |
| Oct 28, 2026 | 1.94 | 2.04 | 1.94 | 2.00 | 4,036 |
| Oct 27, 2026 | 1.97 | 2.03 | 1.96 | 2.03 | 4,992 |
| Oct 26, 2026 | 2.15 | 2.15 | 1.98 | 2.01 | 8,044 |
| Oct 23, 2026 | 2.04 | 2.11 | 2.04 | 2.04 | 1,704 |
| Oct 22, 2026 | 2.07 | 2.17 | 1.99 | 2.06 | 5,196 |
| Oct 21, 2026 | 2.19 | 2.19 | 1.96 | 2.11 | 1,856 |
| Name | Shares | % | Source |
|---|---|---|---|
Highbridge Capital Management, LLC · may incl. warrants· filed Aug 2025 | 173.0M | 7.2% as filed | 13G |
Serlin Philip A Chief Executive Officer | 5.1M | -- | FORM 4 |
Schwartz Aharon Director | 3.7M | 74.4% | FORM 4 |
Mitchell P. Kopin · filed Jan 2025 | 1.9M+680.9K via warrants | 5.0% as filed | 13G |
Zeevi Mali Chief Financial Officer | 1.3M | 26.3% | FORM 4 |
Armistice Capital, LLC · also on 13F· joint filing· may incl. warrants· filed Nov 2026 | 514.4K | 10.3% | 13G |
ARMISTICE CAPITAL, LLC | 473.0K | 9.5% | 13F |
CITADEL ADVISORS LLC | 30.1K | 0.6% | 13F |
SUSQUEHANNA INTERNATIONAL GROUP, LLP | 20.6K | 0.4% | 13F |
STIFEL FINANCIAL CORP | 20.0K | 0.4% | 13F |
Insiders
- Serlin Philip AChief Executive Officer
- Schwartz AharonDirector
- Zeevi MaliChief Financial Officer
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology.
The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.
It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions.
The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
based on 4.98M shares outstanding
30d Avg
11.13K
60d Avg
13.87K
90d Avg
18.15K
Signal8's dilution snapshot of BLRX as of Dec 31, 2025 records an effective F-3 shelf registration (effective Jan 5, 2024), 10 outstanding warrant series and a registered direct offering closed Aug 31, 2026, from SEC filings. BioLineRx Ltd. (NASDAQ: BLRX) traded at $1.12 on Nov 17, 2026, down 2.61% from the previous close of $1.15. 52-week range: $1.11 to $3.95. The company is in the Healthcare sector (Biotechnology).